CMPIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer...

Stats
本日の出来高	63 651.00
平均出来高	233 019
時価総額	0.00
EPS	$-0.730 ( 2022-05-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.85
ATR14	$0.291 (2.77%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-31	Powell Michael	Sell	30 000	Stock Option (Right to Buy)
2022-05-31	Powell Michael	Sell	10 030	Stock Option (Right to Buy)
2022-05-31	Powell Michael	Sell	30 000	Stock Option (Right to Buy)
2022-05-31	Flaherty Keith T.	Sell	10 030	Stock Option (Right to Buy)
2022-05-31	Flaherty Keith T.	Sell	4 012	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 90 transactions
Buy: 10 162 192 \| Sell: 69 692 426

ボリューム相関

長: 0.41 (neutral)

短: -0.45 (neutral)

Signal:(88.816) Neutral

Checkmate 相関

10 最も正の相関
WPRT	0.988
APTO	0.981
ORTX	0.973
RESN	0.969
RXDX	0.969
ZGNX	0.965
ACOR	0.965
IMGN	0.963
PBPB	0.961
GNLN	0.961

10 最も負の相関
EYE	-0.966
IEP	-0.958
PEBK	-0.956
PINC	-0.955
AADI	-0.951
CMLS	-0.95
CPTN	-0.949
MDRX	-0.949
ALHC	-0.946
LCUT	-0.945

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Checkmate 相関 - 通貨/商品

0.09
( neutral )

0.70
( moderate )

0.49
( neutral )

0.50
( weak )

0.64
( weak )

-0.10
( neutral )

Checkmate 財務諸表

Annual	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.42

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.42

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.44

Financial Reports:

No articles found.

Checkmate

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.